Generally when a drug trial is stopped early it is bad news, lack of effectiveness or a serious safety issue. Once in a rare while, a drug is working so well, that it is unfair to keep it from the placebo group and the trial is halted and unblinded. This is what happened to Bristol-Myers Squibb (NYSE: BMY) phase 3 trial for its PD1 immuno-oncology drug nivolumab. Bristol may have given up first mover advantage to fellow big pharma Merck (NYSE: MRK), but it is still a force to be reckoned with in the burgeoning field.
In this episode of Where The Money Is, Motley Fool health care analysts David Williamson and Michael Douglass discuss the trial stoppage and results, give investors background on immuno-oncology, why this drug is so important to Bristol. Watch and find out about why this tent-pole franchise has megablockbuster written all over it.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson owns shares of Merck. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.